Clinical trial
A Multicenter, Phase II Trial of the Safety and Efficacy of Amplimexon® (Imexon for Injection) in Combination With Taxotere® (Docetaxel) for Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT00697060 is registered in ClinicalTrials.gov with AmpliMed Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Phase II Trial of the Safety and Efficacy of Amplimexon® (Imexon for Injection) in Combination With Taxotere® (Docetaxel) for Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Lead sponsor
- AmpliMed Corporation
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- August 31, 2010
- Completion date
- August 31, 2012
- Enrollment
- 0 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.